Anti-PDL1

Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A )...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people...


Whereas vaccines are designed to stimulate tumor antigen-specific immune responses, immune checkpoint inhibitors, in theory, should remove the brakes on...


Results from a phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A ( anti-PDL1 ) shrank tumours (...


Important new data on MPDL3280A ( RG7446, also known as anti-PDL1 ) were presented at the 2013 European Cancer Congress...